BioMed X, a leading independent biomedical research institute, today announced the extension of its ongoing collaboration with Merck. Under the new agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases). The next joint global crowdsourcing project will explore mechanisms of immune senescence and mitochondrial dysfunction in regulatory T cells and other T cell subsets that are shared in human autoimmunity and aging. “We are very grateful for the trust and support we received from Merck over the past eight years since we started our collaboration,” Christian Tidona, Founder and Managing Director of the BioMed X Institute said. “This new agreement with Merck is a great validation of our unique innovation model, showing that it delivers sustained translational value to the early R&D pipelines of our pharma partners.” Merck was the first pharma company to enter a partnership with BioMed X, beginning in 2013. Since then, the partnership has steadily grown and the previously initiated research projects have led to 25 scientific publications on topics such as in-silico design of selective kinase inhibitors, myeloid-derived suppressor cell activity, Golgi stress, and DNA damage, as well as several new potential drug target genes which have been further investigated in pre-clinical studies at Merck. “We are excited to strengthen our ongoing commitment to our partnership with BioMed X,” said Ulrich A.K. Betz, Vice President Innovation at Merck. “As a result of this successful collaboration, multiple innovative discovery projects in new research areas have been started at Merck, including the successful implementation of our open innovation concept ‘outcubation’ published in Nature Biotechnology, and we look forward to the scientific advances to come.” The new research projects will build on this ongoing work, as well as BioMed X’s expertise in the fields of immunology and inflammation and Merck’s in-house discovery capabilities in oncology, immuno-oncology and immunology. Candidates interested in the latest call for proposals in the area of immune senescence are invited to submit a competitive project proposal and apply via the BioMed X crowdsourcing platform at www.bio.mx/apply before July 11, 2021. Additional detailed information about this call for application can be found on the website of the BioMed X Institute at www.bio.mx.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!